Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present in a fireside chat at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference. The event is scheduled for on-demand viewing on May 24, 2022, at 7:00 a.m. ET, accessible through the company's investor relations site. Insmed is known for its first-in-disease therapy for chronic lung disease and has a pipeline aimed at unmet medical needs in inflammatory and pulmonary disorders. The webcast will be available for 30 days post-presentation.
Details
News Market Reaction – INSM
The recorded move for INSM in the trading session of this news was +9.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, NJ,, May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference.
The fireside chat will become available for on-demand viewing on May 24, 2022 at 7:00 a.m. ET and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the presentation date.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-hc-wainwright-annual-global-life-sciences-conference-301548445.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.